Vanguard Group
MBII

Vanguard Group’s Marrone Bio Innovations, Inc. MBII Stock Holding History

Vanguard Group’s Portfolio MBII Stock Details MBII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,004,291
Closed -$4.64M – 4655
2022
Q2 		$4.64M Sell
4,004,291
-541,758
-12% -$566K ﹤0.01% 3414
2022
Q1 		$4.91M Sell
4,546,049
-406,723
-8% -$307K ﹤0.01% 3540
2021
Q4 		$3.57M Sell
4,952,772
-34,393
-0.7% -$27.8K ﹤0.01% 3794
2021
Q3 		$4.49M Buy
4,987,165
+127,810
+3% +$154K ﹤0.01% 3727
2021
Q2 		$8.07M Buy
4,859,355
+285,596
+6% +$477K ﹤0.01% 3322
2021
Q1 		$9.56M Buy
4,573,759
+580,262
+15% +$1.21M ﹤0.01% 3167
2020
Q4 		$4.99M Buy
3,993,497
+457,795
+13% +$546K ﹤0.01% 3353
2020
Q3 		$4.31M Sell
3,535,702
-1,164
-0% -$1.42K ﹤0.01% 3224
2020
Q2 		$4.14M Buy
3,536,866
+106,966
+3% +$98.9K ﹤0.01% 3187
2020
Q1 		$2.8M Buy
3,429,900
+230,525
+7% +$244K ﹤0.01% 3203
2019
Q4 		$3.23M Buy
3,199,375
+508,459
+19% +$616K ﹤0.01% 3311
2019
Q3 		$3.79M Buy
2,690,916
+34,380
+1% +$48.6K ﹤0.01% 3238
2019
Q2 		$3.98M Sell
2,656,536
-8,989
-0.3% -$13.9K ﹤0.01% 3246
2019
Q1 		$4.08M Buy
2,665,525
+84,298
+3% +$129K ﹤0.01% 3208
2018
Q4 		$3.79M Buy
2,581,227
+26,622
+1% +$40.8K ﹤0.01% 3178
2018
Q3 		$4.67M Buy
2,554,605
+303,201
+13% +$588K ﹤0.01% 3264
2018
Q2 		$4.14M Buy
2,251,404
+1,206,357
+115% +$2.25M ﹤0.01% 3266
2018
Q1 		$2.09M Buy
1,045,047
+572,015
+121% +$767K ﹤0.01% 3451
2017
Q4 		$521K Buy
473,032
+84,377
+22% +$86.3K ﹤0.01% 3739
2017
Q3 		$447K Buy
388,655
+73,747
+23% +$83.9K ﹤0.01% 3775
2017
Q2 		$406K Sell
314,908
-25,885
-8% -$36.7K ﹤0.01% 3757
2017
Q1 		$665K Buy
340,793
+800
+0.2% +$1.69K ﹤0.01% 3693
2016
Q4 		$728K Sell
339,993
-42,624
-11% -$88.9K ﹤0.01% 3655
2016
Q3 		$659K Sell
382,617
-24,223
-6% -$29.5K ﹤0.01% 3688
2016
Q2 		$334K Hold
406,840
– – ﹤0.01% 3861
2016
Q1 		$366K Hold
406,840
– – ﹤0.01% 3850
2015
Q4 		$448K Buy
406,840
+1,600
+0.4% +$3.43K ﹤0.01% 3859
2015
Q3 		$855K Buy
405,240
+1,223
+0.3% +$2.38K ﹤0.01% 3683
2015
Q2 		$800K Buy
404,017
+7,663
+2% +$21.7K ﹤0.01% 3731
2015
Q1 		$1.53M Buy
396,354
+35,732
+10% +$132K ﹤0.01% 3503
2014
Q4 		$1.3M Buy
360,622
+8,231
+2% +$21.8K ﹤0.01% 3434
2014
Q3 		$937K Buy
352,391
+80,745
+30% +$540K ﹤0.01% 3526
2014
Q2 		$3.16M Buy
271,646
+142,675
+111% +$1.62M ﹤0.01% 3055
2014
Q1 		$1.8M Buy
128,971
+39,804
+45% +$625K ﹤0.01% 3268
2013
Q4 		$1.59M Buy
89,167
+56,981
+177% +$926K ﹤0.01% 3285
2013
Q3 		$542K Buy
+32,186
New +$452K ﹤0.01% 3532

Vanguard Group's MBII Position: Q3 2022 in Review

Vanguard Group sold out of Marrone Bio Innovations, Inc. (MBII) in Q3 2022, closing a stake of 4,004,291 shares — an estimated $4.64M sold.

Vanguard Group first reported a position in MBII in Q3 2013 and held it in 36 quarters. The position peaked at $9.56M in Q1 2021. 0 funds tracked by Wall St. Rank hold MBII as of Q3 2022.

  • Vanguard Group reported no remaining Marrone Bio Innovations, Inc. position as of Q3 2022 after selling out during the quarter.
  • Vanguard Group sold 4,004,291 Marrone Bio Innovations, Inc. shares in Q3 2022, an estimated $4.64M.
  • Vanguard Group first reported a position in Marrone Bio Innovations, Inc. in Q3 2013 and held it in 36 quarters.
  • Vanguard Group's Marrone Bio Innovations, Inc. position peaked at $9.56M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Marrone Bio Innovations, Inc. as of Q3 2022.

Based on Vanguard Group's 13F filing for Q3 2022, filed 14 Nov 2022.